$0.50
3.92%
Nasdaq, Sep 25, 04:00 pm EDT. Closed.
ISIN
US7574681034
Symbol
RDHL

RedHill Biopharma Ltd. Sponsored ADR Stock price

$0.50
-0.11 17.37% 1M
-0.39 43.81% 6M
-0.53 51.46% YTD
-1.15 69.70% 1Y
-15.66 96.91% 3Y
-5,139.50 99.99% 5Y
-14,579.50 100.00% 10Y
-11,099.50 100.00% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
-0.02 3.92%
ISIN
US7574681034
Symbol
RDHL
Industry

Is RedHill Biopharma Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$3.2m
Enterprise Value
$260.0k
Net debt
positive
Cash
$4.0m
Shares outstanding
50.9b
Valuation (TTM | estimate)
P/E
-
P/S
0.7 | -
EV/Sales
0.1 | -
EV/FCF
negative
P/B
0.7
Financial Health
Equity Ratio
16.8%
Return on Equity
-10.1%
ROCE
-200.4%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$4.4m | -
EBITDA
$-11.9m
EBIT
$-12.3m
Net Income
$-4.6m
Free Cash Flow
$-9.7m
Growth (TTM | estimate)
Revenue
-58.9% | -
EBITDA
47.1%
EBIT
46.7%
Net Income
59.9%
Free Cash Flow
-3.0%
Margin
Gross
-
EBITDA
-272.1%
EBIT
-281.5%
Net
-104.5%
Free Cash Flow
-221.2%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
3.9%
Employees
35
Rev per Employee
$10.0k

RedHill Biopharma Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from RedHill Biopharma Ltd. Sponsored ADR

Dec '25
+/-
%
4.37 4.37
59% 59%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
51% 51%
276%
- Research and Development Expense 2.99 2.99
33% 33%
68%
-12 -12
47% 47%
-272%
- Depreciation and Amortization 0.41 0.41
34% 34%
9%
EBIT (Operating Income) EBIT -12 -12
47% 47%
-281%
Net Profit -4.56 -4.56
60% 60%
-104%

In millions USD.

Don't miss a Thing! We will send you all news about RedHill Biopharma Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RedHill Biopharma Ltd. Sponsored ADR Stock News

Neutral
PRNewsWire
●
26 days ago
Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill's commercial GI business The divestiture of Talicia and the acqu...
Neutral
PRNewsWire
●
27 days ago
Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability -- Realizes substantial value from RedHill's 70% stake in Talicia, currently held within a shared ownership and economic structure, while immediately creating a stro...
Neutral
PRNewsWire
●
2 months ago
The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths -- Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the De...
More RedHill Biopharma Ltd. Sponsored ADR News

Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Mr. Ben-Asher
Employees 35
Founded 2009
Website www.redhillbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today